APA (7th ed.) Citation

Li, J., Wang, L., Lu, Y., Zhou, Y., & Chen, Y. (2025, December). Nafamostat mesylate versus regional citrate anticoagulation for chronic hemodialysis in patients at high risk of bleeding: A single-center, retrospective study. Renal Failure.

Chicago Style (17th ed.) Citation

Li, Jiangtao, Lirui Wang, Yuqiu Lu, Ying Zhou, and Yue Chen. "Nafamostat Mesylate Versus Regional Citrate Anticoagulation for Chronic Hemodialysis in Patients at High Risk of Bleeding: A Single-center, Retrospective Study." Renal Failure Dec. 2025.

MLA (9th ed.) Citation

Li, Jiangtao, et al. "Nafamostat Mesylate Versus Regional Citrate Anticoagulation for Chronic Hemodialysis in Patients at High Risk of Bleeding: A Single-center, Retrospective Study." Renal Failure, Dec. 2025.